- Global Pharma News & Resources

Global Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow at a CAGR of 2.1% during the forecast period 2020-2027

A new research report published by Fior Markets with the title Hypertrophic Cardiomyopathy Therapeutics Market By Type (Anticoagulants Beta Adrenergic Blocking Agents, Antiarrhythmic Agents, Calcium Channel Blockers, And Others), Applications (Hospitals, Clinics, And Others), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast 2020 To 2027.

The global hypertrophic cardiomyopathy therapeutics market is expected to grow from USD 1.20 billion in 2019 to USD 1.42 billion by 2027, at a CAGR of 2.1% during the forecast period 2020-2027. North America accounts for the largest market share in this market. This can be attributed to factors such as government support, rising prevalence of cardiovascular diseases, reimbursement policies, R&D for technological innovation, and better medical infrastructure. Europe is the second-largest market share in the hypertrophic cardiomyopathy therapeutics market. Asia-Pacific is anticipated to increase at a significant growth rate. Increasing target audience, development of medical infrastructure with increasing investment from both private and governmental organisations, and technological innovation.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Some of the key players in the hypertrophic cardiomyopathy therapeutics market are Astra Zeneca Plc, Sanofi S.A., ADVANZ PHARMA Corp (Concordia Healthcare Corp), Pfizer Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Gilead Sciences Inc, Mylan N.V., Bayer AG, and Novartis AG.

By the type of drugs, the market is segmented into anticoagulants beta adrenergic blocking agents, antiarrhythmic agents, calcium channel blockers, and others. The antiarrhythmic drugs segment owns the largest market share, due to the rise in the incidences of cardiac arrhythmias and sedated habits like consumption of alcohol and smoking. The calcium blockers are widely used for reducing chest pain, altering the heart rate and to prevent cerebral vasospasm. This segment is driven by the rise in the geriatric population and obesity. Based on the type of devices, the market can be divided into defibrillators, pacemakers, and others. The pacemakers devices account for the largest market share in this segment due to the rise in the number of heart failure and hypertrophic cardiomyopathy cases. Based on the type of end-user applications, the market is bifurcated into hospitals, clinics, and others.

In 2019, AstraZeneca collaborated with Japanese drug-maker Daiichi Sankyo for USD 6.9 billion for developing a new cancer drug called ‘DS-8201’. It is to be used in the treatment for breast cancer and to treat other mutant tumours.

In 2017, The Food and Drug Administration (FDA) approved the Micra Transcatheter Pacing System (TPS). It is a new type of heart device which provides patients with the most advanced pacing technology. This pacemaker is one-tenth of the size of a traditional pacemaker, and it is also the only leadless pacemaker approved for use by the FDA. This device doesn’t require any surgical “pocket” or cardiac wires (leads) under the skin for delivering pacing therapy.


About the report:
The global hypertrophic cardiomyopathy therapeutics market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 29-Jul-2020